✦ LIBER ✦

Pharmacokinetics of pegylated recombinant human megakaryocyte growth and development factor in healthy volunteers and patients with hematological disorders

✍ Scribed by Hideji Tanaka; Hirotaka Takama; Yasumasa Arai; Junichi Azuma; Ryuzo Ohno; Yasuo Ikeda; Hideaki Mizoguchi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Thrombopoietic effects of pegylated reco

✍ Russell L Basser; John EJ Rasko; Kerrie Clarke; Jonathan Cebon; Michael D Green; 📂 Article 📅 1996 🏛 The Lancet 🌐 English ⚖ 38 KB

Long-term Efficacy of Pegylated Recombin

✍ Yuji Yonemura; Hirosada Miyake; Norio Asou; Hiroaki Mitsuya 📂 Article 📅 2005 🏛 Carden Jennings Publishing 🌐 English ⚖ 85 KB

Improvement of thrombocytopenia followin

✍ Kabaya, K; Shibuya, K; Torii, Y; Nitta, Y; Ida, M; Akahori, H; Kato, T; Kusaka, 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 118 KB

Effects of Pegylated Recombinant Human M

✍ KATSUHIKO HARADA; YOSHIKO TAZUNOKI; YOUICHI IDE; AKIHIKO TAKEUCHI; JUN-ICHI KAWA 📂 Article 📅 2000 🏛 Pharmaceutical Press 🌐 English ⚖ 401 KB

Decreased prothrombotic effects of pegyl

✍ U. NISHIYAMA; T. KUWAKI; H. AKAHORI; T. KATO; Y. IKEDA; H. MIYAZAKI 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 325 KB

Further Examination of Various Administr

✍ Hiromichi Akahori; Masako Ozai; Masumi Ida; Kazunori Shibuya; Takashi Kato; Hiro 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 907 KB